---
title: "Contineum Therapeutics CSO Daniel S. Lorrain disposes of USD 556,791 common shares"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291593149.md"
description: "Contineum Therapeutics CSO Daniel S. Lorrain disposed of USD 556,791 in common shares on June 30 and July 1. He exercised options for 33,009 shares at USD 1.01 and sold 37,179 shares at a weighted average price of approximately USD 15.67-16.24. This transaction reduced his direct stake to 135,202 Class A shares. Additionally, he reported holding 10,110 Class A shares indirectly through his spouse."
datetime: "2026-07-02T21:47:52.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291593149.md)
  - [en](https://longbridge.com/en/news/291593149.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291593149.md)
generator: "portal-rs"
---

# Contineum Therapeutics CSO Daniel S. Lorrain disposes of USD 556,791 common shares

-   Contineum Therapeutics CSO Daniel S. Lorrain cut his direct stake to 135,202 Class A shares in transactions on June 30 and July 1. \* He exercised options at USD 1.01 for 33,009 shares, then sold 37,179 shares at weighted average prices near USD 15.67-16.24. \* He also reported 10,110 Class A shares held indirectly by spouse. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Contineum Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-26-047058), on July 02, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [CTNM.US](https://longbridge.com/en/quote/CTNM.US.md)

## Related News & Research

- [Analyst Reaffirms Buy on Contineum, Highlighting PIPE-791 IPF Upside Despite Muscarinic MDD Trial Setback](https://longbridge.com/en/news/298967821.md)
- [Contineum Therapeutics: Phase 2 MOONLIGHT-1 of JNJ-5120/PIPE-307 fails primary endpoint; drug well-tolerated](https://longbridge.com/en/news/298958462.md)
- [Intuitive Machines director, 10% owner Kamal Ghaffarian disposes of USD 1.46 million in common shares](https://longbridge.com/en/news/298647646.md)
- [Datadog CEO Olivier Pomel disposes of $13.30 million in common shares](https://longbridge.com/en/news/298642170.md)
- [BillionToOne General Counsel Thomas P. Lynch sells 19,962 Class A shares for $1.99 million](https://longbridge.com/en/news/298655496.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**